⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

DuPont to face first trial over C-8 exposure

Published 09/14/2015, 01:51 AM
© Reuters. A view of the Dupont logo on a sign at the Dupont  Chestnut Run Plaza  facility near Wilmington, Delaware
DD
-

By Jessica Dye

NEW YORK (Reuters) - Chemical giant DuPont (NYSE:DD) Monday will face the first trial in litigation from residents near one of its plants in West Virginia who have accused the company of sickening them by emitting a toxic chemical that leaked into their drinking water.

Carla Marie Bartlett is among the approximately 3,500 plaintiffs who have sued DuPont in federal court in Ohio, saying they contracted one of six diseases linked to perfluorooctanoic acid, known as PFOA or C-8. Bartlett said she developed kidney cancer from contaminated water.

Bartlett's will be the first case to go to trial, in an early test of potential liability for the allegedly decades-long leak. A second trial will start Nov. 30.

While DuPont is the named defendant, a recent spin-off of its performance chemicals segment, Chemours Co, will cover Dupont's potential liability, according to a Chemours spokeswoman.

The lawsuits center on DuPont's Washington Works plant in Parkersburg, West Virginia, where the company used C-8 as a processing aid to make products like Teflon non-stick cookware.

Plaintiffs say DuPont used C-8 at the plant since the 1950s and continued even after learning that it was potentially toxic and that it had been discovered in nearby drinking water supplies in Ohio and West Virginia.

DuPont spokesman Daniel Turner said in a statement that knowledge about C-8 has evolved over the past 15 years and that the company has worked with regulators, employees and nearby residents to assess and address health and safety concerns. The company said it has phased out use of C-8 in recent years.

In 2001, residents brought a class action against DuPont over C-8 exposure. DuPont settled in 2004, agreeing to fund medical monitoring programs and install new water treatment systems. It also agreed to convene a panel of scientists to determine whether any diseases were linked to C-8.

That panel concluded there was a probable link between C-8 and six diseases: kidney and testicular cancer, ulcerative colitis, thyroid disease, pregnancy-induced hypertension and high cholesterol.

Class members with one of those diseases then individually sued DuPont. The company agreed not to challenge whether C-8 can cause those diseases, but plaintiffs still must prove it is to blame for their individual illnesses.

DuPont said it believes Bartlett's exposure to C-8 was insufficient to cause health problems, and that other factors, like obesity, may be to blame for her cancer.

© Reuters. A view of the Dupont logo on a sign at the Dupont  Chestnut Run Plaza  facility near Wilmington, Delaware

A lawyer for Bartlett did not return requests for comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.